RecruitingNCT07480720

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease

Sponsor

Elazıg Fethi Sekin Sehir Hastanesi

Enrollment

100 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Graves Disease Graves Ophthalmopathy

Summary

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This retrospective observational study is examining whether Graves disease — an autoimmune thyroid condition that causes overactive thyroid — is associated with changes in the delicate nerve layers at the back of the eye (neuroretinal structures), and whether inflammation markers or thyroid antibody levels relate to these changes. Researchers will review medical records and eye scan (optical coherence tomography) data from Graves disease patients and healthy controls seen at a Turkish hospital between 2018 and 2026. Adults aged 18 and older with a Graves disease diagnosis and available OCT and laboratory data are eligible; those with pre-existing eye diseases like glaucoma, diabetic retinopathy, or poor-quality scans are excluded. No additional procedures are required beyond reviewing existing records and test results. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.